I posted some info about the development of FTY 720 (Fingolimod) for stroke in the drug pipeline but thought I'd post it here as well given the apparent reluctance of some neuro's to consider the impact of CCSVI in people with MS. (The link in that post is open access but you need to register) More info:
The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia
Cerebral ischemia is accompanied by fulminant cellular and humoral inflammatory changes in the brain which contribute to lesion development after stroke.
A tight interplay between the brain and the peripheral immune system leads to a biphasic immune response to stroke consisting of an early activation of peripheral immune cells with massive production of proinflammatory cytokines followed by a systemic immunosuppression within days of cerebral ischemia
(Wonder if that could be "RRMS" in action--activation of peripheral immune cells and proinflammatory cytokines followed by "immunosuppression"?)
Recent work has documented the importance of T lymphocytes in the early exacerbation of ischemic injury.
We found that treatment with FTY720 (1mg/kg) reduced lesion size and improved neurological function after experimental stroke in mice,
Also interesting, at least to me, is this abstract that includes two authors who've done lots of research in MS--H. Offner and AA Vandenbark. If it's been posted before, I missed it.
Effect of experimental stroke on peripheral immunity
The profound damage to the CNS caused by ischemic lesions has been well documented. Yet, relatively little is known about the contribution to and effects on the immune system during stroke.
These novel findings advocate the need to develop or effectively utilize agents that can block early neural splenic activation and modulate immune cells specific for brain antigens as a means to prevent mobilization of T and B cells carrying a cytokine death warrant to the brain.
So, it at least seems to me that the immune response to stroke (ischemia) bears a striking resemblance to the immune response in people with MS--I mean really, T cells, B cells, and an MS drug in the pipeline, FTY 720 (Fingolimod) proposed to treat stroke.
Now, what exactly is it that the neuro's dismiss with CCSVI? Do they think CCSVI either can't or doesn't result in ischemia in people with MS? I truly don't get it.
Take care all--end of rant.